NCT03556982

CART-123 FOR Relapsed/Refractory Acute Myelocytic Leukemia（AML）

CD123-Targeted CAR-T in Treating Patients With Relapsed/Refractory Acute Myelocytic Leukemia（AML）

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences · Academic / Other
• Sex: All
• Age: 14 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and efficiency of CD123-Targeted CAR-T in Treating Patients with relapsed/refractory AML

Detailed description

The relapsed/refractory AML patients will receive FC (F,Fludarabine，C，Cyclophosphamide) chemotherapy followed by infusion of allogenic or autologous CD123-Targeted CAR-T cells.No graft-versus-host disease (GVHD) prevention will be conducted before or after infusion. Dose-limiting toxicity,incidence of adverse events and disease response will be detected post-infusion.

Conditions

• Leukemia, Myeloid, Acute

Interventions

Type	Name	Description
BIOLOGICAL	CART-123 cells	CD123-Targeted CAR-T cells are infused to patient received FC chemotherapy

Timeline

• Start date: 2018-03-01
• Primary completion: 2019-03-01
• Completion: 2020-03-01
• First posted: 2018-06-14
• Last updated: 2018-06-14

Locations

1 site across 1 country: China